Daniel Spasic

Daniel Spasic is an experienced life science executive who was recently appointed as Executive Chairman of Julius Clinical Research.12 Here are some key details about his background and role:

Professional Experience

Daniel Spasic has over 25 years of experience in senior life science executive roles.3 Some highlights of his career include:

• Founder and former CEO of TFS HealthScience, a leading global mid-size Contract Research Organization (CRO)12
• Joined the clinical drug development team at Pharmacia & Upjohn in 19963
• Currently serves as an Executive Advisor at Ampersand Capital Partners, joining in 20233

Current Role at Julius Clinical

In November 2023, Daniel Spasic was appointed as Executive Chairman of Julius Clinical's Board of Directors as part of a growth investment from Ampersand Capital Partners.12 In this role, he will work with the CEO and management team to strengthen Julius Clinical's position and grow the business.1

Expertise and Recognition

• Expertise in biopharma outsourced services (drug discovery, pre-clinical and clinical) and research technology-enabled services3
• Recipient of numerous entrepreneurial achievement awards, including:
  • Swedish National Award as "Man of The Year" by Ernst & Young in 20103
  • "Entrepreneur of The Year" by Founders Alliance and Grant Thornton in 20103

Education

• Technical degree in Chemical Engineering3
• OPM (Owner/President Management) from Harvard Business School34

Board Positions

Daniel Spasic currently serves on the Board of Directors for several companies in the life sciences industry, including:

• iuvo Bioscience (US)
• Avance Clinical (Australia)
• Trialbee (US)
• PathoQuest (France/US)
• Scantox (Denmark)
• Inhalation Sciences (Sweden)35

His extensive experience and industry knowledge make him well-suited to guide Julius Clinical in its next phase of growth and development.